Does reduced E-cadherin expression correlate with poor prognosis in patients with upper tract urothelial cell carcinoma?

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>E-cadherin has emerged as a prognostic factor of urothelial cell carcinoma. In the present work we investigate the relationship between expression of E-cadherin and clinical outcomes, following radical nephroureterectomy for upper tract urothelial cell carcinoma.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases to identify eligible studies published until July 2017.</jats:p> </jats:sec> <jats:sec> <jats:title>Result:</jats:title> <jats:p>Six studies were included in the meta-analysis, with a total of 1014 patients. The pooled hazard ratio (HR) for recurrence-free survivor was 0.69 (95% confidence interval [CI], 0.44–1.09, <jats:italic toggle="yes">I</jats:italic> <jats:sup>2</jats:sup> = 63%, <jats:italic toggle="yes">P</jats:italic> = .04). Also, reduced E-cadherin was not significantly associated with poor cancer-specific survivor (pooled HR, 1.40; 95% CI, 0.66–1.43, <jats:italic toggle="yes">I</jats:italic> <jats:sup>2</jats:sup> = 54%, <jats:italic toggle="yes">P</jats:italic> = .11). The pooled HR for overall survivor was not statistically significant (pooled HR, 0.68; 95% CI, 0.32–1.46, <jats:italic toggle="yes">I</jats:italic> <jats:sup>2</jats:sup> = 80%, <jats:italic toggle="yes">P</jats:italic> = .007). The results of the Begg and Egger tests suggested that publication bias was not evident in this meta-analysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Reduced E-cadherin expression did not appear to be significantly associated with disease prognosis after nephroureterectomy in the meta-analysis. However, further high quality, prospective studies are warranted to better address this issue.</jats:p> </jats:sec>